McKesson Ventures
  • Portfolio
  • News
  • Team
  • About Us
    • Our Approach
    • About McKesson
    • Contact Us

CoverMyMeds Announces Acquisition of Companies RxLightning and FastAuth

by McKesson Ventures | Jun 8, 2025 | Press Releases

Medication access company CoverMyMeds has acquired two new companies: RxLightning, a single destination specialty medication solution, and FastAuth, an automated end-to-end patient access software. The two newly acquired companies will be a key part of CoverMyMeds’...

PM360 Announces the Selections for its 12th Annual Innovations Issue

by McKesson Ventures | Dec 14, 2023 | Press Releases

On Thursday, December 14th, pharmaceutical marketing and trade magazine PM360 announced its list of innovators in the pharmaceutical, biotechnology, medical device, and biotechnology industries. These innovators were named for their achievements across a variety of...

Kathleen Bresette named chief revenue officer at RxLightning

by McKesson Ventures | Jul 10, 2023 | Portfolio News

RxLightning has hired Kathleen Bresette as its first chief revenue officer. Bresette’s experience in the health care industry is expansive. Most recently, she served as vice president of business development and client strategy at DrFirst Inc. She was also previously...

RxLightning Closes $17.5M Series A to Accelerate Growth and Remove Barriers to Essential Specialty Medications

by McKesson Ventures | Jun 6, 2023 | Media Coverage, Press Releases

McKesson Ventures has participated in a $17.5 million Series A round for RxLightning, a platform for streamlining access and affordability for specialty medications. This brings the total the company has raised since its inception to $20.5 million. With RxLightning,...

Recent Posts

  • Latent Raises $80M to Close the Gap Between Diagnosis and Treatment
  • Midi Health Surpasses $1B Valuation, Igniting a New Era for Women’s Health
  • Oath Surgical Announces AI-Native Surgical Centers Powered by NVIDIA
  • Atropos Health Announces AI-Driven Commercial Analytics Solution for Life Science Companies
  • Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking
McKesson Ventures

One Post Street, 21st Floor
San Francisco, CA 94104

IN THE NEWS

ABOUT US

CONTACT US

  • Follow
©2026 McKesson Ventures | Privacy Notice | Disclaimer | Cookie Settings
McKesson Ventures

One Post Street, 21st Floor
San Francisco, CA 94104

©2026 McKesson Ventures | Privacy Notice | Disclaimer | Cookie Settings